26th Mar 2025 Plain language summary of prostate-specific antigen (PSA) response to darolutamide in metastatic hormone-sensitive prostate cancer and its effect on treatment outcomes in the ARASENS trial
18th Oct 2024 Enzalutamide in metastatic hormone-sensitive prostate cancer: A summary of the ARCHES and ENZAMET follow-up studies
21st Jun 2022 Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a plain language summary of the ARASENS trial
